drugset
drugset / Trial / NCT02252406

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

NCT02252406 ↗

Phase 4 Completed 33 enrolled University of Florida
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the effects of ranolazine on different markers of cardiometabolic disease in women with stable angina.

Timeline

Start
2015-09
Primary completion
2018-12-17
Completion
2019-05-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranolazine Small molecule 1000 mg Oral

Indications

metabolic syndrome X